Spectrum Pharmaceuticals Launches Marqibo® (vinCRIStine Sulfate LIPOSOME Injection) And Ships First Commercial Orders
Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, announced today the launch of
Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today the launch of Marqibo. The company also confirmed the shipment of its first commercial orders for Marqibo. “Within two months after the Talon acquisition, we are making Marqibo, our fourth commercial product, available to patients in the US,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “Marqibo fits seamlessly into our existing infrastructure and gives us the leverage to continue to grow our hematology franchise.” Marqibo is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. Marqibo’s approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. In the US, approximately 6,000 patients are diagnosed with ALL on an annual basis of which approximately 1,600 patients can be categorized as Ph- ALL in second or greater relapse. Marqibo can be accessed through Spectrum Therapy Access Resources (STAR) which is a reimbursement support, co-pay assistance, and patient assistance program designed to help patients and healthcare professionals gain appropriate access to drugs. About Spectrum Pharmaceuticals, Inc. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum and its affiliates market four oncology drugs ─ FUSILEV ® (levoleucovorin) for Injection in the U.S.; FOLOTYN ® (pralatrexate injection), also marketed in the U.S.; ZEVALIN ® (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights and MARQIBO ® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion, for which the Company has worldwide marketing rights. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com. About Marqibo® Marqibo is a novel, sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Vincristine, a microtubule inhibitor, is FDA-approved for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. (The encapsulation technology, utilized in this formulation, has been shown to provide prolonged circulation of vincristine in the blood).